Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Wenming Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2586-2868; OpenAlex author ID A5101755675. Sources: ClinicalTrials.gov.

Their work

Papers
5 (first author 0, last author 2)
Trials
3 (principal investigator on 3)
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper · 2024: 1 trial · 2025: 3 papers, 1 trial · 2026: 1 trial

Papers 5

  1. ZEB1 promotes chemoimmunotherapy resistance in pancreatic cancer models by downregulating chromatin acetylation of CXCL16. Co-author DOI 10.1172/jci195970↗
  2. Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancrea… Last author DOI 10.1186/s12916-025-04234-4↗
  3. Feasibility of simplified Patlak parametric imaging with scaled population-based input function on pancreatic cancer. Co-author DOI 10.1186/s40658-025-00758-z↗
  4. Comparing the clinical value of baseline [68 Ga]Ga-FAPI-04 PET/CT and [18F]F-FDG PET/CT in pancreatic ductal adenocarcinoma: additional prognostic value of the… Co-author DOI 10.1007/s00259-023-06297-y↗
  5. Pathological complete response in a patient with locally advanced pancreatic adenocarcinoma treated with neoadjuvant gemcitabine and S-1: a case report and lit… Last author DOI 10.21037/gs-22-6↗

Trials 3

  1. Chimeric Antigen Receptor Macrophages Targeting c-MET for Advanced Stage of Pancreatic Cancer Patients Principal investigator NCT07553793↗
  2. The Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or N… Principal investigator NCT06861543↗
  3. XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer Principal investigator NCT06353646↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Quan Liao · 1 shared trial, 2026 · strength 0.95
  2. Zhixin Hao · 2 shared papers, 2023–2025 · strength 0.40
  3. Li Huo · 2 shared papers, 2023–2025 · strength 0.40
  4. Jiangdong Qiu · 2 shared papers, 2023–2025 · strength 0.40
  5. Taiping Zhang · 2 shared papers, 2023–2025 · strength 0.40
  6. Yumeng Hu · 1 shared paper, 2025 · strength 0.22
  7. Shaobo Zhang · 1 shared paper, 2025 · strength 0.22
  8. Mingyang Liu · 1 shared paper, 2025 · strength 0.22
  9. Fangxia Wang · 1 shared paper, 2025 · strength 0.22
  10. Zhijun Zhou · 1 shared paper, 2025 · strength 0.22
  11. Min Li · 1 shared paper, 2025 · strength 0.22
  12. Haoran Qi · 1 shared paper, 2025 · strength 0.22
  13. Junyi Gao · 1 shared paper, 2022 · strength 0.20
  14. Surong Hua · 1 shared paper, 2022 · strength 0.20
  15. Huan Wang · 1 shared paper, 2025 · strength 0.18
  16. Xue Yang · 1 shared paper, 2025 · strength 0.18
  17. Xiaoyu Yin · 1 shared paper, 2025 · strength 0.18
  18. Tongsen Zheng · 1 shared paper, 2025 · strength 0.18
  19. Xianze Wang · 1 shared paper, 2025 · strength 0.18
  20. Qiang Xu · 1 shared paper, 2025 · strength 0.18
  21. Chuntao Gao · 1 shared paper, 2025 · strength 0.18
  22. Zhihua Li · 1 shared paper, 2025 · strength 0.18
  23. Tao Xia · 1 shared paper, 2025 · strength 0.18
  24. Yuejuan Cheng · 1 shared paper, 2025 · strength 0.18
  25. Heshui Wu · 1 shared paper, 2025 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.